The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PCRX | +27.06% | -59.45% | -16.52% | +228% |
| S&P | +15.06% | +95.03% | +14.29% | +415% |
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $181.10M | 1.7% |
| Gross Profit | $125.91M | 5.4% |
| Gross Margin | 69.53% | 2.4% |
| Market Cap | $1.11B | -16.9% |
| Market Cap / Employee | $1.40M | 0.0% |
| Employees | 790 | 11.0% |
| Net Income | -$4.85M | -125.7% |
| EBITDA | $36.46M | -26.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $300.48M | 21.6% |
| Accounts Receivable | $114.37M | 9.2% |
| Inventory | 148.2 | 43.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $419.39M | -34.4% |
| Short Term Debt | $212.02M | 2217.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.01% | -12.0% |
| Return On Invested Capital | 2.61% | -1.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $9.32M | -82.0% |
| Operating Free Cash Flow | $12.01M | -77.4% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 43.50 | 20.98 | 22.24 | - | |
| Price to Book | 0.93 | 1.16 | 1.48 | 1.39 | -7.14% |
| Price to Sales | 1.00 | 1.32 | 1.65 | 1.54 | -26.51% |
| Price to Tangible Book Value | 2.25 | 2.81 | 3.26 | 3.23 | -36.83% |
| Price to Free Cash Flow TTM | 3.59 | 5.17 | 7.25 | 9.28 | 18.58% |
| Enterprise Value to EBITDA | 20.97 | 21.23 | 53.80 | 34.89 | 2.88% |
| Free Cash Flow Yield | 27.9% | 19.3% | 13.8% | 10.8% | -15.67% |
| Return on Equity | -11.5% | -12.1% | -12.3% | -15.6% | -306.58% |
| Total Debt | $644.42M | $638.85M | $636.46M | $631.40M | -2.65% |
Deaths from prescription opioids have quadrupled since 1999, but new drugs that reduce their use may help end the opioid epidemic.
Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.
PCRX earnings call for the period ending September 30, 2021.
PCRX earnings call for the period ending June 30, 2021.
PCRX earnings call for the period ending March 31, 2021.
PCRX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
